ADPT | tickerfilter.com

Fundamental analysis

37%

Profitability 35%

Dept financing 33%

Liquidity 70%

Performance 31%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-2.29%

1 Month

-7.04%

3 Months

-5.84%

6 Months

7.64%

1 Year

93.86%

2 Year

284.13%

Key data

Stock price

$14.52

P/E Ratio

0.00

DAY RANGE

$14.11 - $15.05

EPS

-$0.39

52 WEEK RANGE

$6.68 - $20.76

52 WEEK CHANGE

$90.55

MARKET CAP

2.479 B

YIELD

N/A

SHARES OUTSTANDING

153.982 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-01-2025

BETA

1.57

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,986,222

AVERAGE 30 VOLUME

$1,717,028

Company detail

CEO: Chad Robins
Region: US
Website: adaptivebiotech.com
Employees: 790
IPO year: 2019

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Adaptive Biotechnologies Corporation develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals. It serves the life sciences research, clinical diagnostics, and drug discovery applications.

ADPT - Adaptive Biotechnologies Corp